
Corticosteroid Exposure and Dupilumab's Impact on Pediatric Growth
Lisa Swanson, MD, explores how pediatric atopic dermatitis, sleep disruption, and dupilumab may influence growth and bone health.
Episodes in this series
As treatment options for pediatric atopic dermatitis (AD) continue to expand, clinicians face important questions about how long-term disease management may influence growth and skeletal development. Although topical corticosteroids remain a cornerstone of AD treatment, concerns about cumulative steroid exposure have prompted greater attention to the relationship between treatment burden, uncontrolled inflammation, and growth-related outcomes in children.
In the second installment of the Dermatology Times Expert Perspectives series, Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis, Lisa Swanson, MD, examines emerging evidence surrounding dupilumab (Dupixent), corticosteroid exposure, and pediatric growth. The discussion explores findings from clinical trials and observational studies, including changes in height percentiles and bone alkaline phosphatase (BALP), a biomarker associated with bone formation.
As researchers investigate whether improved disease control may influence growth trajectories, these findings offer an opportunity to reconsider how clinicians evaluate the potential effects of both AD and its treatments on developing children.
Balancing Corticosteroid Exposure With Disease Control
Topical corticosteroids (TCS) remain an essential component of pediatric AD management, helping reduce inflammation, relieve pruritus, and control disease flares. However, concerns about prolonged or excessive corticosteroid exposure can complicate treatment decisions, particularly among families worried about potential systemic effects.
Although appropriately prescribed topical corticosteroids are generally considered safe, systemic absorption can occur, particularly with high-potency preparations, extensive application, prolonged use, or treatment involving compromised skin barriers. Excessive exposure may raise concerns about hypothalamic-pituitary-adrenal axis suppression and other systemic effects.
At the same time, inadequately controlled AD can contribute to persistent inflammation, disrupted sleep, and substantial disease burden, factors that may also be relevant when evaluating pediatric growth.
This creates an important clinical distinction: whether observed differences in growth are associated with corticosteroid exposure, the underlying inflammatory disease, or a combination of factors.
In the Expert Perspectives discussion, Swanson considers how clinicians can address parental concerns about corticosteroid use while emphasizing the importance of effective disease management.
Examining Dupilumab's Association With Height Percentile Changes
Emerging clinical trial data have raised questions about whether dupilumab treatment may be associated with favorable changes in growth-related outcomes among children with severe AD.
A 2026 post hoc analysis by Irvine and colleagues evaluated height percentile changes in pediatric patients receiving dupilumab compared with placebo, including a subgroup of children whose baseline height fell below the 40th percentile.
Among these children, the odds of achieving a height percentile increase of at least 5 points by week 16 were greater with dupilumab than with placebo.
The analysis reported an unadjusted odds ratio (OR) of 2.5. After adjustment for cumulative topical corticosteroid dose, the OR increased to 3.1, while adjustment for TCS-free days yielded an OR of 2.9.
These findings suggest that the observed association between dupilumab treatment and height percentile improvement was not eliminated after accounting for the measured corticosteroid exposure variables.
However, because the analysis was conducted post hoc, the results should be interpreted as exploratory rather than definitive evidence that dupilumab directly improves linear growth.
The findings also highlight the complexity of separating the potential effects of treatment from those of improved disease control, particularly in children experiencing substantial inflammatory and symptomatic burden.
What Longer-Term Findings Suggest About Treatment Timing
Additional findings from an open-label extension provide further context for interpreting growth-related outcomes during dupilumab treatment.
In the extension, children initially assigned to placebo for 16 weeks subsequently received dupilumab. Investigators observed changes in height percentiles and BALP among these patients that were similar to those seen in children who had received dupilumab throughout the treatment period.
Among children with baseline height below the 40th percentile, 40.4% of those who transitioned from placebo to dupilumab achieved an increase of at least 5 height percentiles between weeks 16 and 52.
Among children who received dupilumab continuously, 50.7% achieved an increase of at least 5 height percentiles between weeks 16 and 52.
These findings suggest that favorable changes in growth-related measures may also occur after initiating dupilumab following an initial period without the biologic.
Nevertheless, the open-label design and exploratory nature of the analyses limit conclusions about the optimal timing of systemic treatment specifically for growth outcomes.
For clinicians, the findings raise questions about whether earlier and more sustained control of severe AD could influence broader developmental measures, particularly among children already tracking at lower height percentiles.
Interpreting Bone Alkaline Phosphatase as a Growth-Related Biomarker
Beyond changes in height percentiles, researchers have examined BALP as a potential indicator of bone formation activity in children receiving dupilumab.
BALP is produced by osteoblasts and reflects aspects of bone formation. In growing children, however, concentrations naturally vary with age and developmental stage, making interpretation more complex than in adults.
Changes in BALP may provide insight into biological processes associated with skeletal development, but they do not directly establish improvements in bone mineral density, bone strength, or long-term skeletal outcomes.
The proposed relationship between dupilumab, improved disease control, and bone formation also remains incompletely understood.
Investigators have suggested that reducing itch and improving sleep could potentially contribute to favorable growth-related changes. However, the referenced post hoc analysis did not directly measure sleep, limiting conclusions about this proposed mechanism.
Consequently, the available data support continued investigation into the relationship between AD treatment and skeletal development rather than definitive claims about dupilumab's effects on bone health.
Putting Clinical Trial Findings Into Real-World Context
Although randomized clinical trials provide valuable evidence about treatment-associated outcomes, observational studies can offer additional perspectives on growth patterns across broader pediatric populations.
A 2025 TriNetX retrospective cohort analysis by Chen and colleagues found that children with AD had a greater risk of height below the fifth percentile compared with matched controls (relative risk, 1.15; 95% CI, 1.12-1.18).
These findings suggest an association between AD and shorter stature, although the retrospective design cannot establish whether the disease itself causes impaired growth.
Additional real-world evidence has examined dupilumab treatment in younger pediatric populations.
An Italian multicenter retrospective study involving 47 children aged 6 months to 5 years found no negative effect of dupilumab on growth over 52 weeks.
Although reassuring, the relatively small sample size and observational design limit the extent to which these findings can be generalized.
Together, these studies contribute to an evolving evidence base suggesting that growth deserves consideration in pediatric AD management, while also underscoring the need for larger prospective studies and longer-term follow-up.
Translating Emerging Evidence Into Pediatric AD Management
For clinicians treating children with moderate to severe AD, emerging growth-related findings add another dimension to discussions about treatment selection and long-term disease control.
Corticosteroid exposure, persistent inflammation, sleep disturbances, and baseline growth patterns may all warrant consideration when evaluating children with substantial disease burden.
However, the available evidence does not establish that dupilumab should be prescribed specifically to improve height or bone density. Treatment decisions must continue to reflect established indications, disease severity, patient age, prior treatment response, and individual clinical circumstances.
As longer-term evidence becomes available, understanding how effective disease management intersects with growth and skeletal health may help inform increasingly comprehensive approaches to pediatric AD care.
Related to this article












